Business Description
Enveric Biosciences Inc
NAICS : 541714
SIC : 2834
ISIN : US29405E4061
Total Employee Number:
6Description
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.92 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 78.1 | |||||
3-Year EPS without NRI Growth Rate | 75.1 | |||||
3-Year FCF Growth Rate | 77.8 | |||||
3-Year Book Growth Rate | -85.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 86.92 | |||||
9-Day RSI | 72.61 | |||||
14-Day RSI | 59.37 | |||||
3-1 Month Momentum % | -65.06 | |||||
6-1 Month Momentum % | -52.58 | |||||
12-1 Month Momentum % | -90.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.66 | |||||
Quick Ratio | 11.66 | |||||
Cash Ratio | 10.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -345.6 | |||||
Shareholder Yield % | -68.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -218.64 | |||||
ROA % | -173.94 | |||||
ROIC % | -4053.25 | |||||
3-Year ROIIC % | -347.79 | |||||
ROC (Joel Greenblatt) % | -4155.71 | |||||
ROCE % | -218.66 | |||||
Moat Score | 1 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.59 | |||||
Price-to-Tangible-Book | 0.59 | |||||
EV-to-EBIT | -0.17 | |||||
EV-to-EBITDA | -0.18 | |||||
EV-to-FCF | -0.18 | |||||
| Price-to-Net-Current-Asset-Value | 0.6 | |||||
| Price-to-Net-Cash | 0.67 | |||||
Earnings Yield (Greenblatt) % | -588.24 | |||||
FCF Yield % | -126.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ENVB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enveric Biosciences Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -27.336 | ||
| Beta | 2.5489 | ||
| 3-Year Sharpe Ratio | -1.15 | ||
| 3-Year Sortino Ratio | -1.53 | ||
| Volatility % | 137.43 | ||
| 14-Day RSI | 59.37 | ||
| 14-Day ATR ($) | 0.129667 | ||
| 20-Day SMA ($) | 1.366 | ||
| 12-1 Month Momentum % | -90.57 | ||
| 52-Week Range ($) | 1.25 - 17.64 | ||
| Shares Outstanding (Mil) | 4.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enveric Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enveric Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 104 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 13 days | ||
| Mind, Muscle & Vision Summit, Hosted by B. Riley Securities | 2026-07-16 12:30 | 1.32 (-0.75%) | ||
| General meeting for 2026 | 2026-05-28 10:00 | 2.14 (-4.04%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 2.29 (-5.37%) | ||
| Needham’s Virtual Psychedelics Forum | 2026-04-27 13:00 | 5.04 (+23.23%) | ||
| Annual report for 2025 | 2026-03-27 | 1.86 (-3.63%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-27 | 1.86 (-3.63%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 5.46 (-7.30%) | ||
| 0.0833333:1 Stock Split | 2025-10-28 | 7.38 (+0.90%) |
Show
Entries
Enveric Biosciences Inc Frequently Asked Questions
What is Enveric Biosciences Inc(ENVB)'s stock price today?
The current price of ENVB is $1.57. The 52 week high of ENVB is $17.64 and 52 week low is $1.25.
When is next earnings date of Enveric Biosciences Inc(ENVB)?
The next earnings date of Enveric Biosciences Inc(ENVB) is 2026-08-14 Est..
Does Enveric Biosciences Inc(ENVB) pay dividends? If so, how much?
Enveric Biosciences Inc(ENVB) does not pay dividend.
Guru Commentaries on NAS:ENVB
No articles.
Press Release
Articles on Enveric Biosciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers